Tidal Investments LLC Buys New Shares in Catalent, Inc. (NYSE:CTLT)

Tidal Investments LLC purchased a new stake in shares of Catalent, Inc. (NYSE:CTLT) in the 3rd quarter, Holdings Channel reports. The fund purchased 3,541 shares of the company’s stock, valued at approximately $214,000.

A number of other hedge funds have also recently bought and sold shares of CTLT. Bank of New York Mellon Corp boosted its holdings in shares of Catalent by 14.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,930,621 shares of the company’s stock valued at $108,559,000 after buying an additional 250,999 shares during the last quarter. Principal Financial Group Inc. grew its position in shares of Catalent by 0.6% in the 2nd quarter. Principal Financial Group Inc. now owns 207,977 shares of the company’s stock valued at $11,695,000 after acquiring an additional 1,283 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in shares of Catalent by 63.1% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 842,136 shares of the company’s stock worth $47,353,000 after purchasing an additional 325,746 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in shares of Catalent by 1.4% in the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,238 shares of the company’s stock valued at $1,082,000 after purchasing an additional 257 shares during the period. Finally, MUFG Securities EMEA plc bought a new stake in shares of Catalent in the 2nd quarter valued at about $13,596,000.

Analyst Ratings Changes

A number of brokerages have weighed in on CTLT. William Blair reissued a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Baird R W lowered Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Robert W. Baird reaffirmed a “neutral” rating and set a $63.50 price target on shares of Catalent in a report on Tuesday, September 24th. Finally, StockNews.com downgraded shares of Catalent from a “hold” rating to a “sell” rating in a report on Tuesday, December 10th. One analyst has rated the stock with a sell rating and seven have assigned a hold rating to the company’s stock. According to data from MarketBeat, Catalent currently has a consensus rating of “Hold” and an average price target of $63.40.

Insiders Place Their Bets

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the transaction, the director now directly owns 10,835 shares of the company’s stock, valued at $646,849.50. The trade was a 20.54 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.31% of the company’s stock.

Catalent Stock Performance

CTLT opened at $63.48 on Thursday. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96. The business has a fifty day simple moving average of $60.69 and a 200 day simple moving average of $59.46. Catalent, Inc. has a 1 year low of $41.15 and a 1 year high of $63.50. The company has a market capitalization of $11.52 billion, a PE ratio of -28.09, a price-to-earnings-growth ratio of 2.70 and a beta of 1.15.

Catalent (NYSE:CTLT) last announced its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same period in the previous year, the firm posted ($0.10) EPS. The company’s revenue was up 4.2% compared to the same quarter last year. Research analysts expect that Catalent, Inc. will post 0.78 EPS for the current year.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.